2004
DOI: 10.1016/j.fertnstert.2004.05.032
|View full text |Cite
|
Sign up to set email alerts
|

Aging and infertility in women

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(2 citation statements)
references
References 44 publications
0
2
0
Order By: Relevance
“…SRI treatment limited to the luteal phase appears to be as effective as daily administration (2937), indicating a much shorter onset of action of these drugs when used for premenstrual dysphoric disorder than when used for depression and anxiety disorders. There is also evidence that certain ovulation-inhibiting hormonal treatments (38, 39) and gonadotropin-releasing hormone (GnRH) agonists (4045) are efficacious in the treatment of premenstrual syndrome/premenstrual dysphoric disorder, and there is no reason to believe that these treatments would be effective in other mood disorders (41). While GnRH agonist treatment appears to be effective for both the behavioral and physical symptoms of premenstrual syndrome/premenstrual dysphoric disorder in the majority of cases, hormone add-back is required to reduce the adverse sequelae of long-term hypogonadism.…”
Section: Addressing Requirements For Diagnostic Categorymentioning
confidence: 99%
See 1 more Smart Citation
“…SRI treatment limited to the luteal phase appears to be as effective as daily administration (2937), indicating a much shorter onset of action of these drugs when used for premenstrual dysphoric disorder than when used for depression and anxiety disorders. There is also evidence that certain ovulation-inhibiting hormonal treatments (38, 39) and gonadotropin-releasing hormone (GnRH) agonists (4045) are efficacious in the treatment of premenstrual syndrome/premenstrual dysphoric disorder, and there is no reason to believe that these treatments would be effective in other mood disorders (41). While GnRH agonist treatment appears to be effective for both the behavioral and physical symptoms of premenstrual syndrome/premenstrual dysphoric disorder in the majority of cases, hormone add-back is required to reduce the adverse sequelae of long-term hypogonadism.…”
Section: Addressing Requirements For Diagnostic Categorymentioning
confidence: 99%
“…Furthermore, in no other psychiatric disorder do SRIs reduce symptoms with as short an onset of action as in premenstrual dysphoric disorder. Likewise, premenstrual dysphoric disorder is responsive to treatment with oral contraceptives containing the unique progestin drospirenone (38, 39) as well as to ovarian suppression with GnRH agonists (45, 46). …”
Section: Addressing Requirements For Diagnostic Categorymentioning
confidence: 99%